RecruitingPhase 4NCT05923905

Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Peking University Third Hospital
Principal Investigator
Fan DongSheng
Peking University Third Hospital
Intervention
FB1006(drug)
Enrollment
64 enrolled
Eligibility
18-80 years · All sexes
Timeline
20232027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05923905 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials